Qisen Guo

机构：Johns Hopkins University, Johns Hopkins Medicine, University of Alabama at Birmingham · ORCID：0000-0003-4304-6431

发表论文 85 篇 · 总被引 1451 次 · h-index 19

代表论文

• Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01) (2022 · Journal of Clinical Oncology · 被引 178)
• Sintilimab versus docetaxel as second‐line treatment in advanced or metastatic squamous non‐small‐cell lung cancer: an open‐label, randomized controlled phase 3 trial (ORIENT‐3) (2022 · 癌症：英文版 · 被引 60)
• Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study (2024 · The Lancet Respiratory Medicine · 被引 21)
• Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial (2024 · Signal Transduction and Targeted Therapy · 被引 16)
• Tislelizumab plus chemotherapy for patients with EGFR -mutated non-squamous non-small cell lung cancer who progressed on EGFR tyrosine kinase inhibitor therapy (2023 · Journal for ImmunoTherapy of Cancer · 被引 14)
• OA21.03 A Phase 3b Study of 1L Savolitinib in Patients with Locally Advanced or Metastatic NSCLC Harboring MET Exon 14 Mutation (2023 · Journal of Thoracic Oncology · 被引 10)